Treatment of chronic lymphocytic leukemia using anti-CD20 antibodies
US8206711B2 · kind B2 · utility
19Cited by
50References
9Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 2, 2009 |
| Grant date | Jun 26, 2012 |
| Priority date | — |
| Expiry date | Dec 9, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.